JOPAMIRON 300 100 ml

Indications

• Management of chronic pain
• Treatment of anxiety disorders
• Adjunct therapy in depression
• Control of certain types of seizures
• Management of fibromyalgia

Dosage

Children: Refer to the BNF for Children for appropriate dosing information tailored to the paediatric population.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated, patient age, and overall health status.

Mechanism of action

Equivelnt acts by interacting with specific receptors or enzymes in the body, which leads to a cascade of biochemical events resulting in the desired therapeutic outcome. This may involve enhancing or inhibiting certain pathways that regulate physiological functions.

Pharmacodynamics

The pharmacodynamics of Equivelnt are characterized by its effects on cellular and systemic processes. The drug may influence neurotransmitter release, modulate receptor sensitivity, or alter enzyme activity, ultimately affecting the physiological state of the patient. The clinical effects are often dose-dependent and can vary based on individual patient factors.

Pharmacokinetics

Equivelnt is absorbed via the gastrointestinal tract, with its bioavailability depending on the formulation and presence of food. It undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, leading to various metabolites. The elimination half-life can vary, influencing dosing schedules. Renal or hepatic impairment may necessitate dosage adjustments to avoid toxicity.

Pregnancy

The safety of Equivelnt during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether Equivelnt is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Iodine deficiency
• Goiter
• Hypothyroidism
• Thyroiditis
• Fibrocystic breast disease

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines based on age and weight.

Adults: Refer to the BNF for appropriate dosing guidelines based on condition and clinical judgment.

Mechanism of action

Molecular iodine inhibits the induction and promotion of carcinogenesis in mammary tissues and has shown beneficial effects in fibrocystic breast disease. It temporarily decreases thyroid hormone production through the acute Wolff-Chaikoff effect, followed by a return to normal hormone synthesis due to down regulation of the sodium-iodide symport. This mechanism can lead to a transient hypothyroid state in some individuals with underlying thyroid conditions.

Pharmacodynamics

Iodine is vital for the synthesis of thyroid hormones thyroxine (T4) and triiodothyronine (T3). It affects the metabolism of amine-derived hormones and plays a role in amino acid metabolism. The acute excess of iodide can lead to decreased circulating levels of T4 and T3 in susceptible individuals, while most people can escape this effect and maintain normal thyroid function.

Pharmacokinetics

Iodine is absorbed primarily in the gastrointestinal tract and is distributed throughout the body, particularly in the thyroid gland, where it is concentrated for hormone synthesis. The kidney plays a significant role in the excretion of excess iodine. The half-life of iodine in the body varies and can be influenced by dietary intake and underlying health conditions.

Adverse effects

• Hypothyroidism
• Hyperthyroidism
• Iodine allergy
• Gastrointestinal disturbances

Interactions

• Thyroid hormones
• Antithyroid drugs
• Lithium
• Diuretics

Precautions

• Use with caution in patients with thyroid dysfunction
• Monitor thyroid function periodically during treatment
• Pregnant or breastfeeding women should consult a healthcare provider before use

Pregnancy

Iodine is essential for fetal thyroid hormone synthesis, but excessive iodine intake should be avoided.

Breast-feeding

Iodine is excreted in breast milk; consult a healthcare provider regarding supplementation.

Storage

Store in a cool, dry place away from light.

Formulations

• Iodine solution
• Iodine tincture
• Potassium iodide tablets

Indications

• Computed tomography (CT) imaging
• Angiography
• Intravenous urography
• Myelography

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidance in paediatric patients, as doses may vary based on age, weight, and specific imaging requirements.

Adults: The typical adult dose for iopamidol varies depending on the specific procedure and imaging requirements. For CT imaging, a common dose is 100-200 mL, administered intravenously. Refer to the BNF for specific dosing recommendations based on the procedure.

Mechanism of action

Iopamidol increases the contrast of vascular structures by absorbing X-rays, which allows for clearer imaging during radiological procedures. It may induce an elevation in serum potassium levels through the release of potassium into intravascular spaces, although studies indicate that the elevation caused by iopamidol is less significant compared to other contrast agents.

Pharmacodynamics

Iopamidol functions primarily as a contrast agent in diagnostic imaging, enhancing the clarity of images by increasing the attenuation of X-rays. Its pharmacodynamic properties include a low osmolality which reduces the risk of adverse reactions compared to high-osmolar contrast agents. The release of potassium may influence electrolyte balance, but the clinical significance of this is generally minimal.

Pharmacokinetics

Iopamidol is administered intravenously and is rapidly distributed in the vascular system. It is not significantly metabolized in the body and is primarily excreted unchanged by the kidneys. The elimination half-life in healthy individuals is approximately 2 hours, with renal clearance being the major route of elimination.

Adverse effects

• Nausea
• Vomiting
• Headache
• Dizziness
• Injection site reactions
• Hypotension
• Allergic reactions including anaphylaxis

Interactions

• Concurrent use with metformin may increase the risk of lactic acidosis in patients with renal impairment
• Other nephrotoxic agents may increase the risk of renal toxicity

Precautions

• Use with caution in patients with renal impairment
• Hydration is recommended to reduce the risk of renal complications
• Monitor serum creatinine levels in patients at risk for contrast-induced nephropathy

Pregnancy

Use only if clearly needed, as the risk to the fetus cannot be ruled out.

Breast-feeding

Iopamidol is excreted in breast milk, but the effects on the nursing infant are unknown. A decision should be made to discontinue breastfeeding or discontinue the drug.

Storage

Store at room temperature, away from light. Do not freeze.

Formulations

• Iopamidol 370 mg iodine/mL solution for injection
• Iopamidol 300 mg iodine/mL solution for injection

Mechanism of action

Molecular iodine is known to inhibit the induction and promotion of N-methyl-n-nitrosourea-induced mammary carcinogenesis, to regress 7,12-dimethylbenz(a)anthracene-induced breast tumors in rats.It has also been shown to have beneficial effects in fibrocystic human breast disease. An acute iodide excess (above the preexisting dietary intake) transiently decreases the production of thyroid hormones in the thyroid gland; this is referred to as the acute Wolff-Chaikoff effect. In normal people, this is followed by a return to normal levels of hormone synthesis, referred to as escape from the acute Wolff-Chaikoff effect, without a significant change in circulating hormone levels. Escape is thought to be the result of down regulation of the sodium-iodide symport (NIS), the iodide transporter in the thyroid gland, resulting in a decrease in the intrathyroidal iodine and the resumption of normal hormone synthesis. An acute or chronic excess of iodide can also decrease circulating T4 and T3 levels and induce a hypothyroid state in some people who have underlying thyroid disorders. These effects are the result of a failure to escape from the acute Wolff-Chaikoff effect. Most people who experience iodine-induced hypothyroidism recover when the excess iodine intake is discontinued.

Mechanism of action

To test the hypothesis that iodinated contrast media may induce an elevation in serum potassium level, /contrast media was administered to rabbits and tested in-vitro according to four protocols./ Protocol A: After intravenous infusion of contrast media into six rabbits, alterations of potassium ion concentrations were measured. Protocol B: Fresh rabbit blood was mixed in vitro with contrast media, and the fluctuations in potassium were monitored over a 30-minute period. Protocol C: Similar to protocol B, except that blood from humans with no reaction to contrast media was used. For protocol A, blood potassium levels increased above baseline levels. The elevations were statistically significant (P < .05). For protocol B, diatrizoate and ioxaglate caused a gradual increase in blood potassium levels, but iopamidol did not. In protocol C, all three contrast media caused statistically significant elevation in potassium levels. The release of potassium was statistically significant at 5 minutes (P < .05 for diatrizoate and ioxaglate, and P < .01 for iopamidol). The mean release rates (+/- standard deviation) by means of linear regression analysis were 0.0190 mmol/min +/- 0.0112 with diatrizoate, 0.0159 mmol/min +/- 0.0057 with iopamidol, and 0.0088 mmol/min +/- 0.0033 with ioxaglate. Iodinated contrast media increase blood potassium levels causing release of potassium into intravascular spaces. This potassium release may play some role in contrast medium-induced adverse reactions. The synthesis of prostaglandins and other metabolic products of arachidonic acid (AA) was investigated in isolated perfused lungs of hamsters during the infusion of various concentrations of meglumine diatrizoate and iopamidol. Forty nmol of (14)C-AA was infused into the pulmonary circulation with radiographic contrast media (RCM), and prostaglandins, thromboxanes, and metabolites of lipoxygenases were analyzed from the nonrecirculating perfusion effluent. Arachidonate infusion increased the perfusion pressure. This pressor response was decreased by iopamidol ... The amount of radioactivity was decreased in the perfusion effluent and increased in lung lipids by iopamidol. ... Almost all arachidonate metabolites were decreased significantly by iopamidol when compared with hypertonic saline ...